+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Neuroendocrine Control of Immunoreactive Growth Hormone and Bioactive Prolactin Secretion in Neonatal Rats: Ontogeny and Interactions between the Serotonergic, Cholinergic and Alpha 2-Adrenergic Systems

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The effects of the α<sub>2</sub>-agonist clonidine (CLO), the serotonin (5-HT) precursor 5-hydroxy-L-tryptophan (5-HTP), the 5-HT<sub>2</sub>/histamine (H<sub>1</sub>) antagonist cyproheptadine (CYPRO), the muscarinic cholinergic antagonist atropine (ATR), and an affinity-purified polyclonal anti-rat growth hormone-releasing hormone (rGHRH) immunoglobulin on serum concentrations of growth hormone (GH) and prolactin (PRL) were tested in 2- and 10-day-old litter-mate rat pups. Serum levels of GH and PRL were detected in RIA and Nb2 lymphoma bioassay, respectively. The effects of two different drugs either alone or in combination with each other were evaluated by two-factor analysis of variance. The data indicated that secretion of GH and PRL was regulated by α<sub>2</sub>-adrenergic, serotonergic and cholinergic mechanisms; the pathways regulating the two hormones, however, were distinct. 5-HTP stimulated GH secretion as early as day 2 postpartum via cholinergic mechanisms not involving GHRH; this pathway was also present in 10-day-old pups. An additional serotonergic pathway was functional in 10-day-old pups which mediated CLO-induced release of GH, and did not include cholinergic transmission. The α<sub>2-</sub>adrenergic regulation of GH secretion appeared to involve three distinct mechanisms: (1) a sexually uniform GH-stimulating α<sub>2</sub>-adrenergic pathway was demonstrated with CLO in 2-day-old pups only after pretreatment with ATR; (2) a sexually dimorphic CLO-induced secretion of GH was observed that was mediated by mechanisms sensitive to CYPRO but not to ATR, and occurred by day 10; and (3) 5-HTP-induced GH secretion was counteracted by CLO in 10-day-old pups of both sexes indicating that a sexually uniform GH-inhibiting α<sub>2</sub>-adrenergic pathway was present. The concentration of PRL was not affected by 5-HTP up to day 10, and was decreased by ATR in 10-day-old (but not in 2-day-old) pups. Secretion of GH and PRL appeared to be stimulated by different sets of cholinergic neurons because (1) ATR inhibited GH secretion on day 2 but inhibition of PRL secretion appeared later, and (2) CLO-induced PRL secretion was diminished by ATR, whereas CLO-induced release of GH was not affected in 10-day-old pups. CYPRO increased serum levels of PRL in 10-day-old pups; thus, PRL-inhibiting network was functional at this age. Whether the inhibition of this pathway was due to the serotonin, histamine (H<sub>1</sub>) or dopamine antagonist action of CYPRO requires further investigation.

          Related collections

          Author and article information

          S. Karger AG
          08 April 2008
          : 57
          : 2
          : 195-203
          Pennsylvania State University, Department of Molecular and Cell Biology, University Park, Pa., USA
          126360 Neuroendocrinology 1993;57:195–203
          © 1992 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Original Paper


          Comment on this article